



NEUROLOGY E-SCRIBE and FAX ENROLLMENT FORM

☐ NOBLE NORTHEAST: E-Scribe: NOBLE | Fax: 888-842-3977 | Tel: 888-843-2040
☐ NOBLE CAROLINAS: E-Scribe: NOBLE | Fax: 888-842-3977 | Tel: 888-743-3204
☐ NOBLE SOUTHEAST: E-Scribe: NOBLEMS/TRANSCRIPT | Fax: 601-420-4040 | Tel: 866-420-4041

Delivery Needed By: _____ Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Other: _____

PATIENT INFORMATION

Patient Name: _____ Male: ☐ Prescriber: _____
Address: _____ Female: ☐ Office Contact: _____
City: _____ State: _____ Zip: _____ Address: _____
Phone: _____ Email: _____ City: _____ State: _____ Zip: _____
Last 4 of SSN: _____ DOB: _____ Phone: _____ Fax: _____
Translator: Yes ☐ No ☐ Language: _____ DEA/NPI #: _____
Patient interested in: Support Programs ☐ Ancillary Supplies ☐ Signature: _____ Date: _____

PRESCRIBER INFORMATION

INSURANCE INFORMATION - PLEASE FAX A COPY OF FRONT & BACK OF PRESCRIPTION CARD

CLINICAL INFORMATION

Diagnosis: _____ ICD-10 Code: _____
Has the patient been treated previously for this condition: Yes ☐ No ☐ Height: _____ ft _____ in Weight: _____ lbs
Allergies: _____ Medications On: _____
Other Notes: _____ Medications Failed: _____

MEDICATION INFORMATION

- | | | |
|---|---|---|
| ☐ Aubagio® (teriflunomide) | ☐ glatiramer acetate injection | ☐ Rebif® |
| ☐ Austedo® | ☐ Glatopa® | ☐ Rebif® Rebidose |
| ☐ Avonex® | ☐ Kesimpta® | ☐ Rebif® Rebidose Titration |
| ☐ Betaseron® | ☐ Mavenclad® | ☐ Rebif® Syringe Titration |
| ☐ Botox® | ☐ Mayzent® | ☐ Tecfidera® (dimethyl fumarate) |
| ☐ Briumvi® | ☐ Novantrone® | ☐ Xenazine® (tetraabenazine) |
| ☐ Copaxone® | ☐ Nurtec® | Generic Only |
| ☐ dalfampridine | ☐ Ocrevus® | ☐ vigabatrin |
| ☐ Elaprase® | ☐ Ocrevus Zunovo™ | ☐ Vumerity® |
| ☐ Extavia® | ☐ Plegridy® | ☐ Zeposia® |
| ☐ Gilenya® (fingolimod) | ☐ Qulipta® | ☐ Other: _____ |

Dosage/Strength:	Route of Administration:	Directions:	Quantity:	Refills:	Dispense as Written:
	☐ Pen ☐ Starter Kit ☐ Syringe ☐ Tablet ☐ Topical ☐ Vial				

NATIONALLY ACCREDITED. 100% EMPLOYEE OWNED. WWW.NOBLEHEALTHSERVICES.COM

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. Q220251